2 assets in Nasal Cavity Carcinoma

Therapeutic assets addressing Nasal Cavity Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Nasal Cavity Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Nasal Cavity Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)